Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia

Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yilin, Han, Linlin, Li, Shiyu, Hu, Tianyu, Xu, Zhiheng, Fan, Yun, Liang, Xiaoniu, Yu, Huan, Wu, Jianjun, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911758/
https://www.ncbi.nlm.nih.gov/pubmed/36759508
http://dx.doi.org/10.1038/s41531-023-00447-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911758/
https://www.ncbi.nlm.nih.gov/pubmed/36759508
http://dx.doi.org/10.1038/s41531-023-00447-7

Ejemplares similares